Your browser doesn't support javascript.
loading
Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease.
Hopp, Katharina; Catenacci, Victoria A; Dwivedi, Nidhi; Kline, Timothy L; Wang, Wei; You, Zhiying; Nguyen, Dustin T; Bing, Kristen; Poudyal, Bhavya; Johnson, Ginger C; Jackman, Matthew R; Miller, Marsha; Steele, Cortney N; Serkova, Natalie J; MacLean, Paul S; Nemenoff, Raphael A; Gitomer, Berenice; Chonchol, Michel; Nowak, Kristen L.
Afiliación
  • Hopp K; Department of Medicine, Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Catenacci VA; Consortium for Fibrosis Research and Translation, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Dwivedi N; Department of Medicine, Division of Endocrinology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Kline TL; Department of Medicine, Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Wang W; Department of Radiology, Mayo Clinic College of Medicine, Rochester, MN 55901, USA.
  • You Z; Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, MN 55901, USA.
  • Nguyen DT; Department of Medicine, Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Bing K; Department of Medicine, Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Poudyal B; Department of Medicine, Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Johnson GC; Department of Medicine, Division of Endocrinology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Jackman MR; Department of Radiology, Mayo Clinic College of Medicine, Rochester, MN 55901, USA.
  • Miller M; Department of Medicine, Division of Endocrinology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Steele CN; Department of Medicine, Division of Endocrinology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Serkova NJ; Department of Medicine, Division of Endocrinology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • MacLean PS; Department of Medicine, Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Nemenoff RA; Department of Radiology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Gitomer B; Department of Medicine, Division of Endocrinology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Chonchol M; Department of Medicine, Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Nowak KL; Consortium for Fibrosis Research and Translation, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
iScience ; 25(1): 103697, 2022 Jan 21.
Article en En | MEDLINE | ID: mdl-35059607
Progression of autosomal dominant polycystic kidney disease (ADPKD) is modified by metabolic defects and obesity. Indeed, reduced food intake slows cyst growth in preclinical rodent studies. Here, we demonstrate the feasibility of daily caloric restriction (DCR) and intermittent fasting (IMF) in a cohort of overweight or obese patients with ADPKD. Clinically significant weight loss occurred with both DCR and IMF; however, weight loss was greater and adherence and tolerability were better with DCR. Further, slowed kidney growth correlated with body weight and visceral adiposity loss independent of dietary regimen. Similarly, we compared the therapeutic efficacy of DCR, IMF, and time restricted feeding (TRF) using an orthologous ADPKD mouse model. Only ADPKD animals on DCR lost significant weight and showed slowed cyst growth compared to ad libitum, IMF, or TRF feeding. Collectively, this supports therapeutic feasibility of caloric restriction in ADPKD, with potential efficacy benefits driven by weight loss.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: IScience Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: IScience Año: 2022 Tipo del documento: Article